(ECAT) BlackRock ESG Capital - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US09262F1003
Stocks, Bonds, Alternatives, Esg, Infrastructure
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 22.70% |
| Yield on Cost 5y | 31.21% |
| Yield CAGR 5y | 54.41% |
| Payout Consistency | 100.0% |
| Payout Ratio | 178.2% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 12.2% |
| Value at Risk 5%th | 21.0% |
| Relative Tail Risk | 4.55% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.62 |
| Alpha | 1.92 |
| CAGR/Max DD | 1.50 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.296 |
| Beta | 0.662 |
| Beta Downside | 0.676 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.79% |
| Mean DD | 2.17% |
| Median DD | 1.54% |
Description: ECAT BlackRock ESG Capital November 12, 2025
BlackRock ESG Capital Allocation Trust (NYSE: ECAT) is a U.S.-based common stock that falls under the GICS sub-industry “Asset Management & Custody Banks,” positioning it within the broader financial services sector that benefits from fee-based revenue streams.
Key data points to consider: (1) As of the latest filing, the trust’s net assets under management (AUM) have grown ~7 % year-over-year, reflecting strong investor demand for ESG-focused products; (2) Its expense ratio sits at 0.65 %, which is competitive relative to peer ESG ETFs that average around 0.80 %; and (3) The sector’s revenue outlook is tied to the Fed’s policy stance-higher interest rates typically compress bond-fund yields but can boost cash-management fees, a dynamic that directly influences ECAT’s net asset value (NAV) growth. These drivers suggest that ECAT’s performance is sensitive to both ESG capital inflows and macro-financial conditions.
For a deeper, data-rich assessment of ECAT’s valuation and risk profile, you may find ValueRay’s analytical dashboards useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (240.6m TTM) > 0 and > 6% of Revenue (6% = 14.7m TTM) |
| FCFTA 0.19 (>2.0%) and ΔFCFTA 10.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -52.37% (prev -40.61%; Δ -11.75pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 338.4m > Net Income 240.6m (YES >=105%, WARN >=100%) |
| Net Debt (-4.27m) to EBITDA (240.6m) ratio: -0.02 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.03 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (99.3m) change vs 12m ago -2.97% (target <= -2.0% for YES) |
| Gross Margin 98.36% (prev 0.0%; Δ 98.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 12.80% (prev 14.80%; Δ -2.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 100.0k (EBITDA TTM 240.6m / Interest Expense TTM 1330 ) >= 6 (WARN >= 3) |
Altman Z'' 0.98
| (A) -0.07 = (Total Current Assets 4.27m - Total Current Liabilities 132.4m) / Total Assets 1.81b |
| (B) 0.04 = Retained Earnings (Balance) 69.6m / Total Assets 1.81b |
| (C) 0.13 = EBIT TTM 240.6m / Avg Total Assets 1.91b |
| (D) 0.45 = Book Value of Equity 69.6m / Total Liabilities 155.7m |
| Total Rating: 0.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.43
| 1. Piotroski 8.0pt |
| 2. FCF Yield 21.91% |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -0.02 |
| 6. ROIC - WACC (= 3.05)% |
| 7. RoE 13.46% |
| 8. Revenue Trend data missing |
| 9. EPS Trend 100.0% |
What is the price of ECAT shares?
As of December 29, 2025, the stock is trading at USD 15.59 with a total of 218,628 shares traded.
Over the past week, the price has changed by -0.13%, over one month by -0.70%, over three months by +0.32% and over the past year by +17.17%.
Over the past week, the price has changed by -0.13%, over one month by -0.70%, over three months by +0.32% and over the past year by +17.17%.
Is ECAT a buy, sell or hold?
BlackRock ESG Capital has no consensus analysts rating.
What are the forecasts/targets for the ECAT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 23.7 | 51.7% |
ECAT Fundamental Data Overview December 26, 2025
Market Cap USD = 1.55b (1.55b USD * 1.0 USD.USD)
P/E Trailing = 7.6373
P/S = 9.8463
P/B = 0.9343
Beta = None
Revenue TTM = 244.6m USD
EBIT TTM = 240.6m USD
EBITDA TTM = 240.6m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -4.27m USD (from netDebt column, last fiscal year)
Enterprise Value = 1.54b USD (1.55b + (null Debt) - CCE 3.38m)
Interest Coverage Ratio = 180.9k (Ebit TTM 240.6m / Interest Expense TTM 1330 )
FCF Yield = 21.91% (FCF TTM 338.4m / Enterprise Value 1.54b)
FCF Margin = 138.4% (FCF TTM 338.4m / Revenue TTM 244.6m)
Net Margin = 98.36% (Net Income TTM 240.6m / Revenue TTM 244.6m)
Gross Margin = 98.36% ((Revenue TTM 244.6m - Cost of Revenue TTM 4.01m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.85 (Enterprise Value 1.54b / Total Assets 1.81b)
Interest Expense / Debt = unknown (Interest Expense 1330 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 190.1m (EBIT 240.6m * (1 - 21.00%))
Current Ratio = 0.03 (Total Current Assets 4.27m / Total Current Liabilities 132.4m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -0.02 (Net Debt -4.27m / EBITDA 240.6m)
Debt / FCF = -0.01 (Net Debt -4.27m / FCF TTM 338.4m)
Total Stockholder Equity = 1.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.28% (Net Income 240.6m / Total Assets 1.81b)
RoE = 13.46% (Net Income TTM 240.6m / Total Stockholder Equity 1.79b)
RoCE = 14.32% (EBIT 240.6m / Capital Employed (Total Assets 1.81b - Current Liab 132.4m))
RoIC = 11.50% (NOPAT 190.1m / Invested Capital 1.65b)
WACC = 8.45% (E(1.55b)/V(1.55b) * Re(8.45%) + (debt-free company))
Discount Rate = 8.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -1.26%
[DCF Debug] Terminal Value 80.13% ; FCFE base≈269.3m ; Y1≈332.2m ; Y5≈566.8m
Fair Price DCF = 89.70 (DCF Value 8.91b / Shares Outstanding 99.3m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 100.0 | EPS CAGR: 0.0% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
P/E Trailing = 7.6373
P/S = 9.8463
P/B = 0.9343
Beta = None
Revenue TTM = 244.6m USD
EBIT TTM = 240.6m USD
EBITDA TTM = 240.6m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -4.27m USD (from netDebt column, last fiscal year)
Enterprise Value = 1.54b USD (1.55b + (null Debt) - CCE 3.38m)
Interest Coverage Ratio = 180.9k (Ebit TTM 240.6m / Interest Expense TTM 1330 )
FCF Yield = 21.91% (FCF TTM 338.4m / Enterprise Value 1.54b)
FCF Margin = 138.4% (FCF TTM 338.4m / Revenue TTM 244.6m)
Net Margin = 98.36% (Net Income TTM 240.6m / Revenue TTM 244.6m)
Gross Margin = 98.36% ((Revenue TTM 244.6m - Cost of Revenue TTM 4.01m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.85 (Enterprise Value 1.54b / Total Assets 1.81b)
Interest Expense / Debt = unknown (Interest Expense 1330 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 190.1m (EBIT 240.6m * (1 - 21.00%))
Current Ratio = 0.03 (Total Current Assets 4.27m / Total Current Liabilities 132.4m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -0.02 (Net Debt -4.27m / EBITDA 240.6m)
Debt / FCF = -0.01 (Net Debt -4.27m / FCF TTM 338.4m)
Total Stockholder Equity = 1.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.28% (Net Income 240.6m / Total Assets 1.81b)
RoE = 13.46% (Net Income TTM 240.6m / Total Stockholder Equity 1.79b)
RoCE = 14.32% (EBIT 240.6m / Capital Employed (Total Assets 1.81b - Current Liab 132.4m))
RoIC = 11.50% (NOPAT 190.1m / Invested Capital 1.65b)
WACC = 8.45% (E(1.55b)/V(1.55b) * Re(8.45%) + (debt-free company))
Discount Rate = 8.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -1.26%
[DCF Debug] Terminal Value 80.13% ; FCFE base≈269.3m ; Y1≈332.2m ; Y5≈566.8m
Fair Price DCF = 89.70 (DCF Value 8.91b / Shares Outstanding 99.3m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 100.0 | EPS CAGR: 0.0% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
Additional Sources for ECAT Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle